EUVIMEDEUVIMED entdecken
Crossref

Survival and Its Predictors Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma in Ethiopia: A 6-Year Follow-Up Study

Abigia Ashenafi iD, Soliyana Demelash, Efrata Melaku, Haymanot Abe, Meron Yitna, Fisseha Tekle, Jiksa Dabessa, Biniam Araya iD, Yared Nigussie, Wondmagegn Demsiss iD, Ashenafi Zelalem, Song Jung Kim und 1 weitere

JCO Global Oncology · 2025

DOI: 10.1200/go-24-00468 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Global Oncology, 2025. Verfasst von Abigia Ashenafi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Myungsung Medical College, Addis Ababa, Ethiopia. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To analyze survival and its predictors among patients with hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE) in Ethiopia. MATERIALS AND METHODS We conducted a retrospective cohort study among patients who received TACE for HCC at MCM Hospital from December 1, 2016, to December 31, 2022. Data were extracted from patients' medical records, and vital status was ascertained from the patients' charts or by phone call to the next of kin. We used Kaplan-Meier estimator to determine survival functions and log-rank test to compare the survival functions in different groups. Predictors of survival were identified using a multivariable Cox proportional hazards regression model as expressed by adjusted hazard ratio (aHR). RESULTS Of the total 257 patients included in the study, 68.9% were male, with a mean age of 56.5 (±14.06) years, and 86% were diagnosed at the advanced stage of the cancer (Barcelona Clinic Liver Cancer-C). The median overall survival was 12.7 months (95% CI, 10.57 to 14.85), and the overall survival rate at 1 year, 2 years, 3 years, 4 years, 5 years, and 6 years was found to be 58.0% (95% CI, 51.8% to 63.8%), 24.1% (95% CI, 19.1% to 29.6%), 8.2% (95% CI, 5.1% to 11.7%), 7.0% (95% CI, 3.9% to 10.1%), 1.6% (95% CI, 0.4% to 3.1%), and 1.2% (95% CI, 0.1% to 2.7%), respectively. The probability of death was significantly increased by alpha-fetoprotein level

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsChemoembolization, TherapeuticHumansMaleFemaleMiddle AgedEthiopiaRetrospective StudiesFollow-Up StudiesAgedAdultSurvival Rate

Autor:innen und Institutionen

  • Department of Medicine, Myungsung Medical College, Addis Ababa, Ethiopia.
  • MCM Comprehensive Specialized Hospital, Addis Ababa, Ethiopia.
  • Department of Public Health, Myungsung Medical College, Addis Ababa, Ethiopia.
  • College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia.
  • School of Public Health, Wachemo University, Hosanna, Ethiopia.

ORCID-Profile: Abigia Ashenafi, Biniam Araya, Wondmagegn Demsiss, Nebiyu Dereje

Zitieren

APA

Ashenafi, A., Demelash, S., Melaku, E., Abe, H., Yitna, M., Tekle, F., Dabessa, J., Araya, B., Nigussie, Y., Demsiss, W., Zelalem, A., Kim, S. J., & Dereje, N. (2025). Survival and Its Predictors Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma in Ethiopia: A 6-Year Follow-Up Study. JCO Global Oncology. https://doi.org/10.1200/go-24-00468

Vancouver

Ashenafi A, Demelash S, Melaku E, Abe H, Yitna M, Tekle F, et al. Survival and Its Predictors Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma in Ethiopia: A 6-Year Follow-Up Study. JCO Global Oncology. 2025. doi:10.1200/go-24-00468

BibTeX
@article{Ashenafi2025,
  author = {Ashenafi, Abigia and Demelash, Soliyana and Melaku, Efrata and Abe, Haymanot and Yitna, Meron and Tekle, Fisseha and Dabessa, Jiksa and Araya, Biniam and Nigussie, Yared and Demsiss, Wondmagegn and Zelalem, Ashenafi and Kim, Song Jung and Dereje, Nebiyu},
  title = {Survival and Its Predictors Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma in Ethiopia: A 6-Year Follow-Up Study},
  journal = {JCO Global Oncology},
  year = {2025},
  doi = {10.1200/go-24-00468}
}
Kostenlos starten →